Serum YKL-40, a new prognostic biomarker in cancer patients? - PubMed (original) (raw)
Review
Serum YKL-40, a new prognostic biomarker in cancer patients?
Julia S Johansen et al. Cancer Epidemiol Biomarkers Prev. 2006 Feb.
Abstract
YKL-40, a member of the "mammalian chitinase-like proteins," is expressed and secreted by several types of solid tumors. The exact function of YKL-40 in cancer diseases is unknown and is an important objective of future studies. YKL-40 exhibits growth factor activity for cells involved in tissue remodeling processes. YKL-40 may have a role in cancer cell proliferation, survival, and invasiveness, in the inflammatory process around the tumor, angiogenesis, and remodeling of the extracellular matrix. YKL-40 is neither organ- nor tumor-specific. However, the present retrospective clinical studies of patients with eight different types of primary or advanced solid tumors suggest that serum concentration of YKL-40 may be a new biomarker in cancer patients used as a "prognosticator." Elevated serum YKL-40 is found in a subgroup of patients with different types of solid tumors, including several types of adenocarcinomas, small cell lung carcinoma, glioblastoma, and melanoma. The highest serum YKL-40 is detected in patients with advanced cancer and with the poorest prognosis. In many cases, serum YKL-40 provides independent information of survival. Serum YKL-40 cannot be used as a single screening test for cancer. The use of serum YKL-40 has not received Food and Drug Administration approval for use as a biomarker for cancer or any other disease. Large multicenter retrospective and prospective studies of patients with different types of cancer are required to determine: (a) if serum YKL-40 is a useful prognostic cancer biomarker, (b) if serum YKL-40 can be of value in monitoring patients with cancer in order to provide information about metastases before these are detected by routine methods, and (c) if serum YKL-40 can be useful for screening of cancer together with a panel of other cancer biomarkers and imaging techniques.
Similar articles
- Plasma YKL-40: a potential new cancer biomarker?
Johansen JS, Schultz NA, Jensen BV. Johansen JS, et al. Future Oncol. 2009 Sep;5(7):1065-82. doi: 10.2217/fon.09.66. Future Oncol. 2009. PMID: 19792974 Review. - High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival.
Johansen JS, Christensen IJ, Riisbro R, Greenall M, Han C, Price PA, Smith K, Brünner N, Harris AL. Johansen JS, et al. Breast Cancer Res Treat. 2003 Jul;80(1):15-21. doi: 10.1023/A:1024431000710. Breast Cancer Res Treat. 2003. PMID: 12889595 - High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer.
Jensen BV, Johansen JS, Price PA. Jensen BV, et al. Clin Cancer Res. 2003 Oct 1;9(12):4423-34. Clin Cancer Res. 2003. PMID: 14555515 - [The importance of determining the prognostic marker YKL-40 in serum and tissues].
Łata E, Gisterek I, Matkowski R, Szelachowska J, Kornafel J. Łata E, et al. Pol Merkur Lekarski. 2010 Jun;28(168):505-8. Pol Merkur Lekarski. 2010. PMID: 20642115 Review. Polish. - Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma.
Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K, von der Maase H. Schmidt H, et al. Cancer. 2006 Mar 1;106(5):1130-9. doi: 10.1002/cncr.21678. Cancer. 2006. PMID: 16456816
Cited by
- Chitinase 3-like 1 expression associated with lymphatic metastasis and prognosis in urothelial carcinoma of the bladder.
Wang B, Chen K, Gao M, Sun X, He W, Chen J, Yang W, Yang T, Qin H, Ruan H, Huang H, Lin T, Huang J. Wang B, et al. Clin Transl Immunology. 2024 Apr 15;13(4):e1505. doi: 10.1002/cti2.1505. eCollection 2024. Clin Transl Immunology. 2024. PMID: 38623539 Free PMC article. - Chitin-mediated blockade of chitinase-like proteins reduces tumor immunosuppression, inhibits lymphatic metastasis and enhances anti-PD-1 efficacy in complementary TNBC models.
Salembier R, De Haes C, Bellemans J, Demeyere K, Van Den Broeck W, Sanders NN, Van Laere S, Lyons TR, Meyer E, Steenbrugge J. Salembier R, et al. Breast Cancer Res. 2024 Apr 11;26(1):63. doi: 10.1186/s13058-024-01815-8. Breast Cancer Res. 2024. PMID: 38605414 Free PMC article. - Strong YKL-40 expression in the invasive tumor front of colorectal cancer-A pilot study.
Kazakova M, Ivanova T, Dikov D, Molander D, Simitchiev K, Sbirkov Y, Dzhambov AM, Sarafian V. Kazakova M, et al. Heliyon. 2024 Mar 7;10(5):e27570. doi: 10.1016/j.heliyon.2024.e27570. eCollection 2024 Mar 15. Heliyon. 2024. PMID: 38495157 Free PMC article. - Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint inhibitors in combination with radiotherapy.
Johansen AZ, Novitski SI, Hjaltelin JX, Theile S, Boisen MK, Brunak S, Madsen DH, Nielsen DL, Chen IM. Johansen AZ, et al. Front Immunol. 2023 Sep 7;14:1228907. doi: 10.3389/fimmu.2023.1228907. eCollection 2023. Front Immunol. 2023. PMID: 37744345 Free PMC article. - Establishment and validation of a clinical nomogram model based on serum YKL-40 to predict major adverse cardiovascular events during hospitalization in patients with acute ST-segment elevation myocardial infarction.
Fang C, Li J, Wang W, Wang Y, Chen Z, Zhang J. Fang C, et al. Front Med (Lausanne). 2023 May 22;10:1158005. doi: 10.3389/fmed.2023.1158005. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37283624 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources